These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 9125158)

  • 1. Competitive inhibition of nitric oxide synthase by p-aminobenzamidine, a serine proteinase inhibitor.
    Venturini G; Menegatti E; Ascenzi P
    Biochem Biophys Res Commun; 1997 Mar; 232(1):88-90. PubMed ID: 9125158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonidine displacement from type 1 imidazoline receptor by p-aminobenzamidine, the prototype of trypsin-like serine protease inhibitors.
    Pallottini V; Marino M; Ascenzi P
    IUBMB Life; 2002 Nov; 54(5):301-4. PubMed ID: 12587981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprotinin, the first competitive protein inhibitor of NOS activity.
    Venturini G; Colasanti M; Ascenzi P
    Biochem Biophys Res Commun; 1998 Aug; 249(1):263-5. PubMed ID: 9705869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gabexate mesylate (FOY), a drug for serine proteinase-mediated diseases, on the nitric oxide pathway.
    Colasanti M; Persichini T; Venturini G; Menegatti E; Lauro GM; Ascenzi P
    Biochem Biophys Res Commun; 1998 May; 246(2):453-6. PubMed ID: 9610382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of bovine beta-trypsin, human alpha-thrombin and porcine pancreatic beta-kallikrein-B by benzamidine and its bis-, tris- and tetra-derivatives: thermodynamic and molecular modeling study.
    Menegatti E; Ferroni R; Nastruzzi C; Bortolotti F; Scalia S; Amiconi G; Bolognesi M; Coletta M; Onesti S; Fruttero R
    Farmaco; 1991 Nov; 46(11):1297-310. PubMed ID: 1811616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BJ-48, a novel thrombin-like enzyme from the Bothrops jararacussu venom with high selectivity for Arg over Lys in P1: Role of N-glycosylation in thermostability and active site accessibility.
    Silva-Junior FP; Guedes HL; Garvey LC; Aguiar AS; Bourguignon SC; Di Cera E; Giovanni-De-Simone S
    Toxicon; 2007 Jul; 50(1):18-31. PubMed ID: 17433397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of nitric oxide synthase inhibition in the acute hypertensive response to intracerebroventricular cadmium.
    Demontis MP; Varoni MV; Volpe AR; Emanueli C; Madeddu P
    Br J Pharmacol; 1998 Jan; 123(1):129-35. PubMed ID: 9484863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KLYP956 is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization.
    Symons KT; Massari ME; Nguyen PM; Lee TT; Roppe J; Bonnefous C; Payne JE; Smith ND; Noble SA; Sablad M; Rozenkrants N; Zhang Y; Rao TS; Shiau AK; Hassig CA
    Mol Pharmacol; 2009 Jul; 76(1):153-62. PubMed ID: 19364813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of nitric oxide formation by neuronal nitric oxide synthase by quinones: nitric oxide synthase as a quinone reductase.
    Kumagai Y; Nakajima H; Midorikawa K; Homma-Takeda S; Shimojo N
    Chem Res Toxicol; 1998 Jun; 11(6):608-13. PubMed ID: 9625728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide.
    Kotsonis P; Fröhlich LG; Shutenko ZV; Horejsi R; Pfleiderer W; Schmidt HH
    Biochem J; 2000 Mar; 346 Pt 3(Pt 3):767-76. PubMed ID: 10698705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous inactivation of human tryptase involves conformational changes consistent with conversion of the active site to a zymogen-like structure.
    Selwood T; McCaslin DR; Schechter NM
    Biochemistry; 1998 Sep; 37(38):13174-83. PubMed ID: 9748324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of nitric oxide on fentanyl and haloperidol-induced catalepsy in mice.
    Erkent U; Iskit AB; Onur R; Ilhan M
    Eur J Anaesthesiol; 2006 Jul; 23(7):580-5. PubMed ID: 16507184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide synthase inhibitors affect nitric oxide synthesis in normoxic but not in ischemic organs during intestinal ischemia and early reperfusion.
    Kozlov AV; Sobhian B; Duvigneau JC; Costantino G; Gemeiner M; Nohl H; Redl H; Bahrami S
    J Lab Clin Med; 2002 Nov; 140(5):303-11. PubMed ID: 12434131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ethanol on neutrophil recruitment and lung host defense in nitric oxide synthase I and nitric oxide synthase II knockout mice.
    Greenberg SS; Ouyang J; Zhao X; Parrish C; Nelson S; Giles TD
    Alcohol Clin Exp Res; 1999 Sep; 23(9):1435-45. PubMed ID: 10512307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes.
    Boer R; Ulrich WR; Klein T; Mirau B; Haas S; Baur I
    Mol Pharmacol; 2000 Nov; 58(5):1026-34. PubMed ID: 11040050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of nitric oxide synthase isoforms by tris-malonyl-C(60)-fullerene adducts.
    Wolff DJ; Papoiu AD; Mialkowski K; Richardson CF; Schuster DI; Wilson SR
    Arch Biochem Biophys; 2000 Jun; 378(2):216-23. PubMed ID: 10860539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of new sulfur-containing L-arginine-derived inhibitors of nitric oxide synthase.
    Ichimori K; Stuehr DJ; Atkinson RN; King SB
    J Med Chem; 1999 May; 42(10):1842-8. PubMed ID: 10346937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of a nitric oxide synthase inhibitor counteracts prostaglandin F2-induced luteolysis in cattle.
    Skarzynski DJ; Jaroszewski JJ; Bah MM; Deptula KM; Barszczewska B; Gawronska B; Hansel W
    Biol Reprod; 2003 May; 68(5):1674-81. PubMed ID: 12606417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermodynamic criterion for the conformation of P1 residues of substrates and of inhibitors in complexes with serine proteinases.
    Qasim MA; Lu SM; Ding J; Bateman KS; James MN; Anderson S; Song J; Markley JL; Ganz PJ; Saunders CW; Laskowski M
    Biochemistry; 1999 Jun; 38(22):7142-50. PubMed ID: 10353824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.
    Dhir A; Kulkarni SK
    Eur J Pharmacol; 2007 Jul; 568(1-3):177-85. PubMed ID: 17509558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.